Skip to main content

Cushing's Disease

Endocrinology
12
Pipeline Programs
5
Companies
4
Clinical Trials
1 recruiting
5
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
5
6
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
583%
Small Molecule
117%
+ 4 programs with unclassified modality

Endocrinology is a $1.4B mature market dominated by legacy products and characterized by significant patent cliff exposure in the near-term.

$1.4B marketMature→ Stable30 products15 companies

Key Trends

  • Two blockbusters (FORTEO, SYNTHROID) approaching LOE with $780M combined spend
  • Growth phase products (ORGOVYX, TYMLOS) entering peak revenue years through 2040
  • Heavy trial activity (625 total) concentrated in Phase 3 and Phase 4 studies indicating established disease focus

Career Verdict

Endocrinology offers stability and specialized expertise but limited growth upside; best suited for professionals comfortable in mature markets seeking deep disease knowledge rather than explosive market expansion.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1FORTEODeclining
$425M
Eli Lilly and Company·LOE_APPROACHING
#2SYNTHROIDDeclining
$355M
AbbVie·LOE_APPROACHING
#3ORGOVYXStable
$277M
#4TYMLOSStable
$198M
Radius Health·PEAK13.5yr

Drug Class Breakdown

Parathyroid Hormone Analogs
$425M(30%)

LOE approaching; potential for new mechanisms

Thyroid Replacement (T3/T4 synthesis)
$379M(27%)

Mature, multiple generics; limited differentiation

GnRH Receptor Antagonists
$278M(20%)

Growth trajectory through 2037

Growth Hormone Analogs (Somatropin)
$27M(2%)

Stable; multiple biosimilars in market

CYP11B1 Inhibitors (Cortisol management)
$45M(3%)

Emerging niche for rare endocrine disorders

Career Outlook

Stable

Endocrinology offers deep specialization and stable employment but limited growth trajectory; market maturity and patent cliff exposure create restructuring risk for legacy product teams at large pharma. Career advancement depends on niche expertise (rare endocrine disorders, bone metabolism) and willingness to work at smaller or specialist biotech firms where hiring is concentrated. Compensation is moderate relative to other therapeutic areas, with Medical Affairs and Clinical Operations commanding premiums.

Breaking In

Prioritize roles at Neurocrine Biosciences or other specialist firms over large pharma to gain endocrinology depth; seek Clinical Operations or IT positions for better compensation and career stability.

For Experienced Professionals

Experienced professionals should pursue Medical Affairs or senior Clinical Operations roles (highest salaries) or consider pivoting to emerging indications (GnRH antagonists in non-prostate oncology, novel PTH mechanisms) to avoid legacy product decline.

In-Demand Skills

Regulatory affairs (navigating complex endocrinology indications and biosimilar pathways)Health economics and market access (managing mature market competition)Clinical trial operations (Phase 3/4 expertise given trial distribution)Real-world evidence and outcomes research (post-approval monitoring of legacy products)

Best For

Medical Science Liaison (strong compensation, focused disease education)Clinical Operations Manager (11% of roles, $210K avg)Regulatory Affairs Specialist (managing LOE transitions and generic competition)Market Access Analyst (managing pricing pressure on thyroid and bone products)

Hiring Landscape

$115K-$359K

Endocrinology hiring is concentrated at specialist biotech firms (Neurocrine: 126 jobs, 93% of available positions) rather than large pharma, indicating a niche market dynamic. IT roles dominate openings (51 jobs, $201K avg) followed by R&D (21 jobs, $120K avg), suggesting company-level digitalization and data infrastructure needs. Compensation ranges widely ($115K-$359K), with Medical Affairs offering premium salaries ($359K) but minimal openings (6 jobs).

135
Open Roles
3
Companies Hiring
5
Departments

Top Hiring Companies

3Stable

By Department

IT(38%)
$201K
Research & Development(16%)
$120K
Commercial(13%)
$115K
Clinical Operations(11%)
$210K
Medical Affairs(4%)
$359K

Limited total opportunity (135 jobs) concentrated at one biotech firm signals a tight job market; IT and Clinical Operations offer best compensation, but specialized endocrinology roles are scarce.

On Market (5)

Approved therapies currently available

Corcept Therapeutics
KORLYMApproved
mifepristone
Corcept Therapeutics
Progestin Antagonist [EPC]oral2012
229M Part D
Recordati
SIGNIFORApproved
pasireotide
Recordati
Somatostatin Analog [EPC]subcutaneous2012
1M Part D
Recordati
SIGNIFOR LAR KITApproved
pasireotide
Recordati
intramuscular2014
Corcept Therapeutics
MIFEPRISTONEApproved
mifepristone
Corcept Therapeutics
Progestin Antagonist [EPC]oral2019
Corcept Therapeutics
MIFEPREXApproved
mifepristone
Corcept Therapeutics
oral2000

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
5 programs
4
1
Pasireotide s.c.Phase 4Peptide
PasireotidePhase 3Peptide
Pasireotide sub-cutaneousPhase 3Peptide
osilodrostatPhase 3Small Molecule
pasireotide LARPhase 3Peptide
Corcept Therapeutics
Corcept TherapeuticsCA - Redwood City
2 programs
1
MifepristonePHASE_31 trial
mifepristonePHASE_3
Active Trials
NCT01371565Completed4Est. Sep 2012
Recordati
RecordatiFrance - Saint-Victor
1 program
1
PasireotidePHASE_4Peptide1 trial
Active Trials
NCT01794793Completed337Est. Jul 2023
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
1
mifepristonePhase 31 trial
Active Trials
NCT01925092Withdrawn0
Lundbeck
LundbeckDenmark - Copenhagen
1 program
1
Lu AG13909Phase 21 trial
Active Trials
NCT06471829Recruiting18Est. Oct 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
RecordatiPasireotide
Human BioSciencesmifepristone
Corcept TherapeuticsMifepristone
LundbeckLu AG13909

Clinical Trials (4)

Total enrollment: 359 patients across 4 trials

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Start: Jun 2013Est. completion: Jul 2023337 patients
Phase 4Completed

Mifepristone in Children With Refractory Cushing's Disease

Start: Aug 20130
Phase 3Withdrawn

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

Start: Nov 2010Est. completion: Sep 20124 patients
Phase 3Completed

A Trial of Lu AG13909 in Adult Participants With Cushing's Disease

Start: Jun 2024Est. completion: Oct 202718 patients
Phase 2Recruiting

Related Jobs in Endocrinology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 359 patients
Peptide is the dominant modality (83% of programs)
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.